Tilaknagar Industries Q2 Profit Falls to Rs 22 Crore; Revenue Surges

CONSUMER-PRODUCTS
Whalesbook Corporate News Logo
AuthorIshaan Verma|Published at:
Tilaknagar Industries Q2 Profit Falls to Rs 22 Crore; Revenue Surges

Tilaknagar Industries posted a significant jump in Q2 FY2027 revenue to Rs 2,437.56 crore, though profit declined to Rs 22.27 crore. Investors should note the auditor's qualified opinion regarding the ENA plant impairment and recent boardroom leadership changes.

Tilaknagar Industries Q2 FY2027 Results and Board Updates

Revenue for Q2 FY2027 reached Rs 2,437.56 crore, compared to Rs 896.92 crore in Q2 FY2026. Quarterly profit stood at Rs 22.27 crore, down from Rs 52.68 crore in the corresponding period last year.

Reader Takeaway: Revenue growth remains strong, but the auditor’s qualified opinion on asset impairment and lower profits demand caution.

What just happened

Tilaknagar Industries released its Q2 and H1 FY2027 unaudited results, reporting a massive expansion in top-line revenue. Simultaneously, the company announced a boardroom reshuffle, with two independent directors stepping down and two new members appointed to the board and various committees effective October 31, 2026.

Why this matters

The auditor, M/s. Harshil Shah & Company, issued a qualified conclusion regarding the company's failure to perform an impairment assessment for an ENA plant. This is a significant point for investors as it directly relates to asset valuation under Ind AS 36 standards. Additionally, the company is managing exceptional integration costs of Rs 10.95 crore for the quarter.

Strategic Developments

The firm continues to expand its footprint through strategic investments. It invested Rs 2 crore in Round the Cocktails Pvt Ltd (RTCP), bringing its stake to 41.45% on a fully diluted basis. Furthermore, it completed a Rs 5.99 crore investment in Black Tiger Distilleries Pvt Ltd, securing a 12.5% equity stake.

Risks to watch

Beyond the auditor’s qualification on impairment, investors should track the progress of the composite scheme of amalgamation, which is still awaiting final regulatory and legal clearances. The company also faces challenges in reconciling its high top-line growth with shrinking bottom-line profitability amid ongoing corporate restructuring.

What to track next

Watch for management commentary regarding the ENA plant impairment and any potential catch-up assessments. Future quarterly filings will reveal how effectively the company can convert its massive revenue surge into healthier net margins as integration costs stabilize.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.